A Look at BMY - Bristol-Myers Squibb

Data from sec.gov is now on emriches.com, under the "Stocks in Scope" menu.

Thoughts:

• Recent acquisition of Celgene added debt and shares outstanding but also increased revenues substantially

• PE ratio misleading due to one time acquisition charges.

• BMY has strong portfolio of drugs aimed at fighting cancer. Generally, the FDA is more likely to approve cancer drugs vs other categories.

• BMY's Opdivo and Merck's Keytruda are the best two cancer treatments on the market. I say; own BMY, and own MRK too.